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Abnormalities in monocytes and in peripheral blood dendritic cells (DC) subsets have been reported in systemic lupus
erythematosus (SLE).We aim to clarify the tolerogenic or inflammatory role of these cells based on ICOSL or IFN-α and chemokine
mRNA expression, respectively, after cell purification. The study included 18 SLE patients with active disease (ASLE), 25 with
inactive disease (ISLE), and 30 healthy controls (HG). In purified plasmacytoid DC (pDC) was observed a lower ICOSL mRNA
expression in ASLE and an increase in ISLE; similarly, a lower ICOSL mRNA expression in monocytes of ALSE patients was
found. However, a higher ICOSL mRNA expression was observed in ASLE compared to HG in myeloid DCs. Interestingly, clinical
parameters seem to be related with ICOSL mRNA expression. Regarding the inflammatory activity it was observed in purified
monocytes and CD14−/low CD16+ DCs an increase of CCL2, CXCL9, and CXCL10 mRNA expression in ASLE compared to HG.
In myeloid DC no diﬀerences were observed regarding chemokines, and IFN-αmRNA expression. In pDC, a higher IFN-αmRNA
expression was observed in ASLE. Deviations in ICOSL, chemokine, and IFN-α mRNA expression in peripheral blood monocytes
and dendritic cells subpopulations in SLE appear to be related to disease activity.
1. Introduction
Systemic lupus erythematosus (SLE) is a multisystemic dis-
ease resulting from an abnormal immunological function
that aﬀects several organ systems characterized by a broad
spectrum of clinical manifestations and a multitude of
cellular abnormalities. The primary pathological findings in
SLE patients are inflammation, vasculitis, immune complex
deposition, and vasculopathy [1–3]. The exact etiology still
remains unclear; however defective clearance of apoptotic
material and/or aberrant apoptosis, in combination with
susceptible genetic background have been suggested to be
involved in SLE development and progression [4–6].
SLE patients exhibit numerous aberrations in the
immune system, comprising B cells, T cells, monocytes,
and dendritic cells, resulting in B and T cell activation and
consequent autoantibodies production against a large variety
of autoantigens [2].
Abnormalities in monocyte phenotype and function
have been identified in several autoimmune disorders,
including SLE, which could contribute to disease patho-
genesis [7, 8]. Likewise, dendritic cells (DCs) subsets are
also implicated in SLE pathogenesis and progression [4, 9].
Recent studies have described alterations in the number
of peripheral blood (PB) DCs, namely myeloid (mDC)
and CD14−/lowCD16+ subsets, in their ability to produce
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inflammatory cytokines, activation status, and chemokine
receptors expression [10, 11].
The immunologic self-tolerance breakdown, particularly
in the control of self- and non-self-discrimination, results
in the development of autoimmune diseases. Therefore,
elucidate the mechanisms that regulate self-tolerance is
important to understand self-directed immune responses
and the mechanisms underlying autoimmune diseases [12,
13]. The notable functional plasticity of DCs, their lineage
and maturational status, stimulation by pathogen-derived
products, the net eﬀect of antigen dose, and cytokine milieu
determine whether an immunogenic or tolerogenic response
will be developed [14].
One important mediator of DCs tolerogenic activity
is ICOSL (inducible costimulator ligand), which is mainly
expressed in pDC, mDCs, immature B cells, and monocytes
and appears to be involved in the induction of a suppressive
eﬀect in T cells under an inflammatory environment as seen
in SLE [15]. ICOS is a costimulator molecule expressed
on CD4+ T cells, which was associated with secretion of
interleukin 10 (IL-10) [15–17]. IL-10 is produced by T cells
and induces tolerance and anergy in eﬀector T cell [18]. ICOS
is expressed at high levels in Th2 and at low levels in Th1 cells
and the expression of this molecule inhibits the secretion of
IL-2 [16]. The activation of ICOS/ICOSL pathway induces a
diﬀerentiation of eﬀector T cells in regulatory T cell and a
sustained Th2 response [19, 20].
SLE is characterized by an inflammatory immune
response mediated, in part, by cytokines and chemokines
produced by antigen presenting cells (APC) and other
immune cells, contributing for disease development and
progression.
Multiple links of evidence support the involvement of
IFN-α in the primary pathogenesis of SLE; high levels of
serum IFN-α have been detected in SLE patients and have
long been related with SLE pathogenesis [21]. Plasmacytoid
DC (pDC) subpopulation is an important mediator of
antiviral immunity through their extraordinary ability to
secrete high levels of IFN-α in response to many DNA and
RNA viruses and, in this sense, has been closely related to
SLE physiopathology [22, 23].
There is a growing evidence suggesting that infiltration
of T lymphocytes and other leukocytes into the sites of
inflammation plays a critical role in organ involvement
in SLE [24]. Chemokines have an important role in the
migration and homing, necessary for the initiation of a
cellular immune response in the sites of inflammation, and
are able to regulate a diﬀerential recruitment of T helper
(Th1 and Th2) lymphocytes [25].
Alterations in the cytokine and chemokine profile in SLE
patients compared to normal controls have been described
and reflect alterations in the inflammatory environment [2,
26, 27]. Chemokines like CCL2, CXCL10, CXCL9, CCL4, and
CCL5 present raised levels in SLE patients serum and may be
related to disease activity, contributing to the inflammatory
disorder [28, 29].
In this context, we evaluated the regulatory function of
peripheral blood monocytes, mDCs, CD14−/lowCD16+ DCs,
and pDCs subsets by the ICOSL mRNA expression and, on
the other hand, we assessed the inflammatory role of these
cells by the mRNA expression of IFN-α and the chemokines
CCL2, CXCL9, CXCL10, CCL4, and CCL5.
2. Methods
2.1. Patients and Samples. Forty-three SLE patients were
enrolled in the study, eighteen with active disease (ASLE)
(100% female, mean age 33± 11 years) and twenty-five with
inactive disease (ISLE) (84% female, mean age 33±10 years).
Patients were recruited fulfilling the 1997 American College
of Rheumatology (ACR) classification criteria for SLE [30].
All patients are followed at the Lupus Clinic, Rheumatology
Department of the University Hospital of Coimbra. After
assessing disease activity at the time of evaluation, according
to the SLE Disease Activity Index 2000 (SLEDAI 2k) [30, 31],
SLE patients were divided into two groups, one with active
(SLEDAI 2k ≥ 5; n = 18) and the other with inactive
(SLEDAI 2k < 5; n = 25) SLE [32]. The patients medication,
at time of evaluation and additional clinical and therapeutic
regimen, was recorded at the time of analysis (Table 1).
The healthy control group (HG) consisted of 30 healthy
individuals (90% female; mean age 30 ± 6 years). These
participants were required to complete a brief question-
naire regarding previous or current medical conditions. All
were free from autoimmune disease, active inflammatory
condition and were not undergoing treatment with any
immunomodulatory drugs.
K3-EDTA-anticoagulated peripheral blood samples were
collected from each participant and FACS-sorted within 18
hours after collection.
2.2. Ethics. The study protocol was approved by the local
ethics committee. All participants gave and signed informed
consent and the principles of Helsinki Declaration were
respected.
2.3. Cell Sorting of Monocytes, CD14−/lowCD16+DC, mDCs,
and pDCs. For the cell sorting of monocytes, CD14−/low
CD16+ DC, mDCs, and pDCs, 3mL of each K3-EDTA PB
sample were added to 10mL of NH4Cl solution (Sigma,
St. Louis, MO, USA) in order to lyse red blood cells.
After 20 minutes of incubation, samples were centrifuged
(5 minutes, at 540×g) and the cell pellet was stained with
the following monoclonal antibodies (mAb): anti-CD16 flu-
orescein isothiocyanate (FITC) (Sanquin–Pelicluster, Ams-
terdam, The Netherlands), anti-CD33 phycoerythrin (PE),
anti-CD45 peridinin chlorophyll protein (PerCP) (BDB,
San Jose, CA, USA), anti-HLA-DR phycoerythrin cyanine
7 tandem (PECy7) (BDB), and anti-CD123 allophycocyanin
(APC) (MacsMiltenyi Biotec, Bergisch Gladbach, Germany).
Once incubated for 20 minutes at room temperature in
the darkness, the cells were washed and resuspended in
phosphate-buﬀered saline (PBS) (Gibco BRL-life Technolo-
gies, Vienna, Austria).
Cell sorting and purification were performed in FAC-
SAria II cell sorter (BDB) using the FACSDiva soft-
ware (BDB). Monocytes were identified and sorted by
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Table 1: Clinical findings in 43 patients with systemic lupus
erythematosus (SLE).
ASLE ISLE
(n = 18) (n = 25)
Mean SLEDAI scores 9.7 ± 3.2 1.6 ± 0.9
Mean time since diagnosis 7.6 ± 7.4 9.0 ± 6.0
Lupus nephritis 44.4% 61.3%
Neurolupus 0% 19.4%
Lupus arthritis 66.7% 58.1%
Haematological involvement 100% 87.1%
Lupus cutaneous involvement 77.8% 74.2%
Severe Lupus∗ 44.4% 71%
Anti-dsDNA antibodies∗∗
Low positive 11.1% 32.3%
Moderately positive 22.2% 22.6%
High positive 55.6% 6.5%
Treatment
Hydroxychloroquine 94.4% 87.1%
Immunossupressants∗∗∗ 66.7% 32.3%
Steroids∗∗∗∗ 83.4% 12.9%
Low dose 46.6% 100%
Moderate dose 33.3% 0%
High dose 20.1% 0%
ASLE: Active disease group.
ISLE: Inactive disease group.
∗Lupus severity in accordance with cumulative major organ involvement.
∗∗Anti-dsDNA antibodies: low positive (<20 IU); moderately positive (20–
50 IU); high positive (>50 IU).
∗∗∗Azathioprine, mycophenolate mo1etil, cyclosporine, tacrolimus,
methotrexate, cyclophosphamide, or rituximab.
∗∗∗∗Low dose, upto 10mg/day; moderate dose, 10–30mg/day; high dose,
more than 30mg/ day; n = sample investigated.
HLA-DR+/CD33high/CD45high phenotype, and the three
DCs subpopulations, characterized by intermediate for-
ward (FSC) and side scatter (SSC) between those of
lymphocytes and monocytes, were purified according to
the following immunophenotype features: myeloidDCs
(mDCs) present HLA-DRhigh/CD33high/CD16neg/CD123dim
immunophenotype, CD14−/lowCD16+ DC subset are HLA-
DRinter/CD33inter/CD123inter, and plasmacytoid DCs (pDC)
are HLA-DRhigh/CD123highCD33neg/ dim/CD16neg (Figure 1)
[33, 34]. The number of cells obtained of each cell population
after FACSAria cell sorting is described in Table 2.
After cell sorting, the purity of the isolated cell popu-
lations was evaluated in the FACSCanto II flow cytometer
(BDB) using the FACSDiva software (BDB) and acquiring a
representative number of sorted cells, and it was consistently
greater than 90%.
2.4. Gene Expression Analysis after Sorting of Monocytes,
Dendritic Cells Subsets. Sorted cell populations were cen-
trifuged for 5 minutes at 300 g and the pellet was resus-
pended in 350 μL of RLT Lysis Buﬀer (Qiagen, Hilden,
Germany) and the total RNA extraction was performed
with the RNeasy Micro kit (Qiagen) according to the
supplier’s instructions. Total RNA was eluted in a 14 μL
volume of RNase-free water. In order to quantify the
amount of total RNA extracted and verify RNA integrity,
samples were analyzed using a 6000 Nano Chip kit, in an
Agilent 2100 bioanalyzer (Agilent Technologies, Waldbronn,
Germany) and 2100 expert software, according to the
manufacturer’s instructions. RNA was reverse transcribed
with SuperScript III First-Strand Synthesis SuperMix for
qRT-PCR (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer’s instructions. Relative quantification of gene
expression by real-time PCR was performed in the LightCy-
cler 480 II (Roche Diagnostics, Rotkreuz, Switzerland). Real-
time PCR reactions were carried out using 1X QuantiTect
SYBR Green PCR Master Mix (Qiagen), 1X QuantiTect
Primer Assay (IFNA1 QT00201964, ICOSLG QT00004669,
CCL2QT00212730, CCL4QT01008070, CCL5QT00090083,
CXCL9 QT00013461, and CXCL10 QT01003065) (Qiagen),
and 20 ng of cDNA sample, in a total volume of 10 μL.
The reactions were performed using the following thermal
profile: 15min at 95◦C, 50 cycles of 15 sec at 94◦C, 30 sec at
55◦C, and 30 sec at 72◦C. Melting point analysis was done to
ensure amplification of the specific product. Real-time PCR
results were analyzed with the LightCycler software (Roche
Diagnostics). GeNorm Reference Gene Selection kit (Primer
Design Ltd., Southampton, UK) in conjunction with the
geNorm software (Primer Design Ltd.) were used to select
the reference genes to normalize data. The reference genes
used for gene expression analysis in monocytes were ATP
synthase (ATP5B) and the beta-2-microglobulin (B2M);
in mDC and CD14−/lowCD16+ DC were the B2M and
ubiquitin-c (UBC); in pDC were the B2M and ATP5B. The
normalized gene of interest expression levels were calculated
by using the delta-Ct method [35].
2.5. Statistical Analyses. Statistical evaluation of data was
analyzed using the nonparametric Mann-Whitney U test
between the studied groups. All statistical analyses were
performed using IBM SPSS statistics 20 software (Armonk,
NY, USA) and diﬀerences were considered as statistically
significant when the P value was less than 0.05.
3. Results
3.1. Frequency of Peripheral Blood Monocytes, CD14−/low
CD16+ DCs, mDCs, and pDCs in SLE Patients and Healthy
Control Group. As shown in Table 3, frequency of peripheral
blood mDCs and pDCs was lower in ASLE group than in
control group, particularly pDCs. A lower pDC frequency
was also observed in ISLE group compared to HG. In con-
trast, no significant diﬀerences were found in the frequency
of circulating monocytes and CD14−/lowCD16+ DCs.We also
verified a lower absolute number of monocytes in ASLE
compared to HG as well as a lower number of peripheral
blood pDCs in SLE patients, especially in ALSE group.
Since the number of dendritic cells obtained after cell
sorting was significantly lower than those of monocytes,
we only evaluated the mRNA expression of IFN-α, ICOSL,
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Figure 1: Flow cytometry gate strategy to obtain purified monocytes and peripheral blood dendritic cells by cell sorting.
CXCL9, and CXCL10 on mDCs and CD14−/lowCD16+
dendritic cells and of IFN-α and ICOSL on pDCs (Table 2).
3.2. Tolerogenic Role of Monocytes, CD14−/lowCD16+ DCs,
mDCs, and pDCs Based on ICOSL mRNA Expression. Con-
cerning the tolerogenic function of monocytes and DCs
subsets, a lower mRNA expression of ICOSL was observed
in ASLE compared to HG in monocytes (Figure 2(b)) and,
on the other hand, an increased ICOSL mRNA expression in
mDCs from both SLE groups compared to HG, was found
(Figure 4(a)).
No significant diﬀerences were observed in CD14−/low
CD16+DC subset between the studied groups (Figure 3(a)).
Moreover, in pDC subpopulation, a lower ICOSL mRNA
expression in ASLE and higher in ISLE compared to HG was
observed (Figure 5(b)).
3.3. Inflammatory Role of Monocytes, CD14−/lowCD16+ DCs,
mDCs, and pDCs Based on Chemokines and IFN-α mRNA
Expression. In purified monocytes was observed a significant
increase of CXCL9 and CXCL10 mRNA expression in both
SLE groups compared to HG (Figures 2(d) to 2(e)). Similarly
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Table 2: Number of sorted monocytes and peripheral blood dendritic cells in the three studied groups (HG, ASLE, and ISLE).
HG ASLE ISLE
(n = 30) (n = 18) (n = 25)
Number of sorted cells
Monocytes 143701 ± 110950 91029 ± 83915 115407 ± 10558
CD14−/lowCD16+ DCs 15393 ± 18486 9667 ± 11976 7251 ± 3903
mDCs 8709 ± 7107 4365 ± 3228 3771 ± 3076
pDCs 5281 ± 3894 1363 ± 1291 3416 ± 2655
HG: Healthy control group.
ASLE: Active disease group.
ISLE: Inactive disease group.
Table 3: Frequency and absolute value of monocytes and peripheral blood dendritic cells in the three studied groups (HG, ASLE, and ISLE).
HG ASLE ISLE
(n = 30) (n = 18) (n = 25)
Frequency (%)
Monocytes 3.9 ± 0.97 3.02 ± 1.61 3.56 ± 1.32
CD14−/lowCD16+ DCs 0.54 ± 0.29 0.45 ± 0.30 0.55 ± 0.33
mDCs 0.29 ± 0.18∗ 0.21 ± 0.15∗∗ 0.29 ± 0.32
pDCs 0.10 ± 0.07∗ 0.02 ± 0.03 0.07 ± 0.07∗∗∗
Absolute Value (cells/μL)
Monocytes 284,6 ± 84,2∗ 193,3 ± 97,5 228,4 ± 87,1
CD14−/lowCD16+ DCs 39,2 ± 23,2 28,1 ± 20 34,1 ± 19,1
mDCs 21,4 ± 15,1 13,9 ± 11,1 18,2 ± 14
pDCs 7.08 ± 5.16∗ 1.24 ± 1.28∗∗ 3.82 ± 3.51∗∗∗
Note: results are expressed as mean ± standard deviation.
Statistically significant diﬀerences were considered when P < 0.05 (Mann-Whitney U test): ∗HG versus ASLE; ∗∗ASLE versus ISLE., ∗∗∗HG versus ISLE.
HG: healthy control group.
ASLE: active disease group.
ISLE: inactive disease group.
a higher mRNA CCL2 expression was observed in ASLE
compared to HG and ISLE (Figure 2(c)). Moreover CCL4
mRNA expression was higher in ISLE, reaching statistical
significance when compared with ASLE group (Figure 2(f)).
Regarding IFN-α and CCL5 mRNA expression, no diﬀer-
ences were found between the studied groups (Figures 2(a)
and 2 (g)).
In CD14−/lowCD16+ DC subset a higher CXCL10 and
CXCL9 mRNA expression in ASLE was noted, when com-
pared with HG, and in the latter chemokine, when compared
with ISLE (Figures 3(c) to 3(d)). The evaluation of the IFN-
α mRNA expression did not present significant diﬀerences
between the studied groups (Figure 3(b)).
Regarding the mDCs subpopulation, we did not found
statistical significant diﬀerences for IFN-α, CXCL9, and
CXCL10 mRNA expression between the studied groups
(Figures 4(b) to 4(d)).
IFN-α mRNA expression evaluated on pDC subset
revealed a significant increase in both SLE groups when
compared with HG, particularly in ALSE (Figure 5(a)).
3.4. ICOSLmRNA Expression and Clinical Parameters. When
we grouped SLE patients based on the amount of anti-
dsDNA antibodies in negative, low (<20 IU), moderate (20–
50 IU), and high positive (>50 IU), we found, in pDC,
an increase on ICOSL mRNA expression in the groups
without anti-dsDNA antibodies and lower positive, when
compared with moderate and high positive groups. Inline
with this observation, we also detected a significant increase
of ICOSL expression in mDC on negative group and in
a lower extension in high positive group, when compared
with lower and moderate positive groups. Moreover, in
CD14−/lowCD16+DC, we found a decrease on ICOSL expres-
sion on moderate-positive group when compared with high-
positive and negative groups (Figure 6).
Concerning cutaneous involvement, we found, in SLE
patients without this clinical feature, an increase on ICOSL
mRNA expression in pDC. Also, an increase of its expression
was observed in mDC in patients with this clinical parameter
(Figure 7).
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Figure 2: IFN-α, ICOSL, CCL2, CXCL9, CXCL10, CCL4, and CCL5 relative gene expression in cell-sorted monocytes in the three studied
groups (HG, ASLE, and ISLE).
No more statistical significant diﬀerences were found
relating other clinical parameters and/or other studied
molecules.
4. Discussion
Monocytes and DCs are involved in the host defense and
regulation of inflammation, playing a critical role in both
adaptive and innate immune responses and in tolerance
development. SLE is a variable autoimmune inflammatory
condition, associated to tissue destruction wherein several
abnormalities and disturbances have been attributed to these
cells in SLE [8, 26, 36].
The tolerogenic function mainly attributed to pDC is, in
part, mediated by the expression of ICOSL which has the
ability to generate anergy in T cells and induce diﬀerentiation
of naive T cells into regulatory T cells [32, 37, 38].
The lower levels of ICOSL mRNA expression observed
in pDC from ASLE patients could be related to the higher
inflammatory peripheral environment, due to increased
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Figure 3: IFN-α, ICOSL, CXCL9, and CXCL10 relative gene expression in cell-sorted CD14−/lowCD16+ DCs subset in the three studied
groups (HG, ASLE, and ISLE).
levels of proinflammatory cytokines and the presence of
circulating immune complexes, which is inline with the
higher levels of IFN-α mRNA found in these cells. The
opposite was observed in ISLE, namely, higher mRNA
expression of ICOSL and lower of IFN-α. This pattern of
ICOSL expression in pDC was also observed in SLE patients
without anti-dsDNA antibodies or with lower levels, as well
as in the group of patients without skin involvement.
In fact, the lower mRNA expression of ICOSL and the
mechanisms involved in ICOS/ICOSL pathway are related to
loss of tolerance to self-antigens that occur in SLE, especially
in patients in active phase [32, 37, 38]. It is described that
the absence of interaction of ICOS with its ligand overrides
the induction of anergy in T cells, considered the first step
in the diﬀerentiation of T helper cells into T suppressor
cells [15]. The reduction of ICOSL expression may also be
explained, at least in part, by a negative feedback mechanism
by which high levels of ICOS lead to the decrease of ICOSL
expression. Since it was reported that active SLE patients
have an increased expression of ICOS on CD4+ and CD8+ T
cells, thus, apparently, exists a negative correlation between
these two molecules [16, 39]. Results of Yang et al. showed
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Figure 4: ICOSL, IFN-α, CXCL9, and CXCL10 relative gene expression in cell-sorted mDCs subset in the three studied groups (HG, ASLE,
and ISLE).
a decreased expression of ICOS on CD4+ and CD8+ T cells
from ISLE patients when compared with ASLE, resulting in a
possible increase of ICOSL in these patients [16].
As observed in pDC, ICOSL mRNA expression in
monocytes is reduced when compared to the HG, probably
due to the same mechanisms observed in pDC. On contrary,
high mRNA expression of this molecule was observed in
mDC from ASLE and, in a lower extent, for ISLE patients
when compared with control group, which could mean
that this subpopulation of dendritic cells is less sensitive to
the peripheral inflammatory environment, probably due to
the fact that the majority of peripheral blood mDCs are
recent immigrates from bone marrow with an immature
phenotype, which could be particularly true in SLE patients,
where an increase migration of these cells to peripheral
tissues could induce an increase in the hematopoiesis of this
cell lineage [40, 41]. In line with this explanation is the
fact that no statistical significant diﬀerences were observed
in this cells for IFN-α and chemokines mRNA expression
among the studied groups. Furthermore the more immature
status of mDC could be also the explanation for the higher
mRNA expression of ICOSL found in patients with skin
involvement, to where occurs an increased mDC migration.
Previous data have reported elevated levels of IFN-α in
the SLE patient’s serum [42, 43], which is in agreement
with the higher mRNA expression of this cytokine in pDC
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Figure 5: IFN-α and ICOSL relative gene expression in cell-sorted pDCs subset in the three studied groups (HG, ASLE, and ISLE).
from SLE patients, particularly in those with active disease.
Dall’Era et al. and Kirou et al. related the serological levels of
IFN-α with SLE clinical manifestations and disease activity
[42, 44].
IFN-α is a pleiotropic cytokine, important in the immune
regulation, that is produced bymultiple cell types in response
to viral infection. pDCs have a special role in the IFN-α
production and are the most important sources of serum
interferon [45]. IFN-α can aﬀect multiple cell types involved
in SLE and has the potential to influence the development,
progression, and pathogenesis of SLE as it can control the
function and activation states of most important immune
cell subsets and function as a bridge between innate and
adaptive immunity [46].
Some studies have demonstrated that the frequency of
circulating pDCs is markedly reduced in SLE patients [47,
48]. However, functional studies revealed that pDCs, upon
stimulation, have a normal IFN-α producing capacity, which
means that aberrant pDC activation may be an important
step in autoimmune diseases like SLE. In fact, an important
finding was that the immune complexes present in SLE
patients serum contain nucleic acids that are internalized via
the FcγRIIa, reach the endosome, and stimulate TLR7 and/or
TLR9, leading to subsequent activation of transcription
factors and IFN-α production [49, 50].
Several studies have revealed the important role of
chemokines and IFN-α in SLE activity. Many have reported
high levels of those in the serum as well as of mRNA
chemokine expression in peripheral blood leukocytes of
these patients, particularly in active disease [29, 51, 52].
DCs subtypes have individual functions and appear to
influence multiple processes that may activate or regulate
autoreactive B cells. Part of their influence is dictated by their
receptors and cytokines profiles and also by their location
[9]. In the present study the use of purified peripheral blood
monocytes and DCs subpopulations emphasizes the role of
these cells in SLE pathophysiology, based on their chemokine
expression.
The altered chemokines mRNA expression observed on
monocytes in SLE patients, namely, in ASLE, is in accordance
with the abnormalities already observed in these patients
[8, 53]. The high levels of CCL2, CXCL9, and CCL4 mRNA
expression observed on monocytes from SLE patients are
consistent with other reports that have found increased levels
in serum from these patients [52, 54]. These findings may be
associated to the IFN-α pathway, since higher levels of IFN-α
have been associated with increased levels of chemokines in
SLE patients, suggesting an upregulation of this chemokine
production according to Bauer et al. studies [28, 54]; likewise
Quiong Fu has suggested the importance of type I IFN
system in modulating chemokine expression, linking these
two networks in the SLE pathogenesis [55].
Moreover, the inflammatory environment of SLE may
lead to chemokine imbalance, including monocyte mobi-
lization. CCL2 is involved in monocyte recruitment into
focus of active inflammation and may act as a potent factor
in the polarization of Th0 cells toward a Th2 phenotype
[56]. In turn, there is increasing evidence that CXCL10
levels are elevated in serum and in tissues of SLE patients,
contributing to a large variety of SLE manifestations [57].
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Figure 6: ICOSL relative gene expression in cell-sorted monocytes and DCs subsets, according to the amount of anti-dsDNA antibodies:
negative; low, moderate, and high positive.
Furthermore, according to Kong et al. data, CXCL10 levels
correlate positively with SLE disease activity and may
represent a fair marker for monitoring disease activity [58].
As reported by Karonitsch et al., CXCL10 and CXCL9 mRNA
expressions in monocytes were increased in SLE patients,
associated with increased responsiveness of monocytes to
IFN-γ, confirmed by mRNA levels of IFN-inducible STAT-
1–dependent CXCL10 and CXCL9 genes [59].
Like monocytes, CD14−/lowCD16+ DC subpopulation
presented higher levels of CXCL9 and CXCL10 mRNA
expression in ASLE group. This data point to a common
role of these cells in SLE pathophysiology, as we previously
reported [10].
Apparently less sensitive to microinflammatory changes
than monocytes, CD14−/lowCD16+ DC express FcγRII
CD16+ [60], which allow these cells to respond to periph-
eral activators motifs like circulating immune complexes.
Moreover, these cells are tissue derivated, reentering in
the peripheral circulation, as previously reported [61, 62],
reflecting in the periphery the tissue injure.
As we previously described, no significantly diﬀerences
on CXCL9 and CXCL10 mRNA expression in mDC were
Clinical and Developmental Immunology 11
HG No Yes
Monocytes
0
0.5
1
1.5
IC
O
SL
 r
el
at
iv
e 
ge
n
e 
ex
pr
es
si
on
(a)
HG No Yes
0
1
2
3
IC
O
SL
 r
el
at
iv
e 
ge
n
e 
ex
pr
es
si
on
CD14−/low CD16+ DCs
(b)
HG No Yes
0
0.5
1
1.5
2
2.5
IC
O
SL
 r
el
at
iv
e 
ge
n
e 
ex
pr
es
si
on
mDCs
∗∗∗
∗∗∗
considered when P < 0.05. Mann-Whitney U test
Note: HG: healthy control group
No: patients with no cutaneos involvement
Yes: patients with cutaneos involvement
Statistically significant differences were
(c)
HG No Yes
0
0.5
1
1.5
2
2.5
IC
O
SL
 r
el
at
iv
e 
ge
n
e 
ex
pr
es
si
on
∗∗∗
pDCs
(d)
Figure 7: ICOSL relative gene expression in cell-sorted monocytes and DCs subsets, according to the cutaneos involvement of SLE patients.
observed in SLE patients, when compared with the control
group. In agreement with our data, Gerl et al. reported no
diﬀerences in the expression of CCR7, CCR1, and CCR5
chemokine receptors in mDC from SLE patients [11].
In conclusion our data clearly demonstrates a diﬀerent
role for monocytes and DCs subsets in SLE pathophysiology.
In active disease, peripheral blood monocytes and
CD14−/lowCD16+ DCs exhibit an upregulation of chemokine
expression, probably due to a higher activation status in the
periphery, contributing to the recruitment of neutrophils,
monocytes/macrophages, and T and NK cells to peripheral
tissues.
In turn, pDCs upregulate IFN-α and downregulate
ICOSL mRNA expression in ASLE, exhibiting a pro-inflam-
matory profile and, conversely, in ISLE they seem to display
a more tolerogenic activity.
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